阿扎胞苷联合低剂量高三尖杉酯碱-阿糖胞苷-粒细胞刺激因子方案治疗老年急性髓系白血病患者的效果  

Effects of Azacitidine Combined with Low-Dose Homoharringtonine-arabinosylcytidine-Granulocyte colony Stimulating Factor Regimen in Treating Elderly Patients with Acute Myeloid Leukemia

作　　者：张雯佳 ZHANG Wenjia(Department of Hematology,Zhengzhou Central Hospital,Zhengzhou Henan 450007,China)

机构地区：[1]郑州市中心医院血液内科,河南郑州450007

出　　处：《临床研究》2025年第5期35-37,共3页Clinical Research

摘　　要：目的分析阿扎胞苷联合低剂量高三尖杉酯碱-阿糖胞苷-粒细胞刺激因子(HAG)方案在老年急性髓系白血病(AML)临床治疗中的应用价值。方法选取郑州市中心医院2022年5月至2024年6月收治的40例老年AML患者并随机分为两组,21例对照组患者接受低剂量HAG方案联合地西他滨治疗,19例研究组患者接受低剂量HAG联合阿扎胞苷治疗。两组患者治疗2个疗程后,评估其临床缓解效果、治疗前后CD3^(+)T细胞、CD4^(+)T细胞以及CD8^(+)T细胞水平变化,统计并对比不良反应发生率。结果对照组疾病缓解率(85.71%)与研究组(89.47%)比较,差异无统计意义(P>0.05)。治疗2个疗程后,两组患者的T细胞亚群水平均低于治疗前,且研究组患者CD3^(+)T细胞、CD4^(+)T细胞、CD8^(+)T细胞水平均高于对照组,差异有统计学意义(P<0.05)。对照组患者不良反应发生率(47.62%)高于研究组(15.79%),差异有统计学意义(P<0.05)。结论阿扎胞苷联合低剂量HAG方案对老年AML患者免疫细胞影响较小,患者不良反应发生率更低,治疗安全性较理想。Objective To analyze the clinical application value of azacitidine combined with low-dose homoharringtonine-arabinosylcytidine-granulocyte colony stimulating factor(HAG)regimen in the treatment of elderly patients with acute myeloid leukemia(AML).Methods Forty elderly AML patients treated at Zhengzhou Central Hospital from May 2022 to June 2024 were randomly divided into two groups.The control group consisting of 21 patients received low-dose HAG combined with decitabine,while the study group consisting of 19 patients received low-dose HAG combined with azacitidine.After two treatment courses,clinical remission effects,changes in CD3^(+)T cells,CD4^(+)T cells,and CD8^(+)T cells levels before and after treatment were evaluated,and the incidence of adverse reactions was compared.Results The disease remission rate in the control group was 85.71%,compared to 89.47%in the study group,with no statistically significant difference(P>0.05).After two treatment courses,T cell subset levels in both groups were lower than before treatment,and CD3^(+)T cell,CD4^(+)T cell,and CD8^(+)T cell levels in the study group were higher than those in the control group,with statistically significant differences(P<0.05).The incidence of adverse reactions was higher in the control group(47.62%)than in the study group(15.79%),with statistically significant differences(P<0.05).Conclusion The combination of azacitidine with low-dose HAG regimen has a smaller impact on immune cells and a lower incidence of adverse reactions in elderly AML patients,indicating favorable treatment safety.

关 键 词：急性髓系白血病 老年患者 阿扎胞苷 低剂量HAG方案 地西他滨 

分 类 号：R733.71[医药卫生—肿瘤]